We found previously that integrinβ1-driven SRC activation is involved in enhanced cell migration and invasiveness as well as the acquisition erlotinib-resistance in human lung cancer cells harboring activated mutant EGFR, and integrinβ1 knockdown or inactivation overcomes drug resistance [33]. This evidence concerns the gene SRC and lung cancer.